Search
Nuvation Bio Inc
NUVBAdd to Watchlist
5.420USD
-0.260-4.58%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.89BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-4.58%
5 Days
-16.10%
1 Month
+9.27%
6 Months
-39.51%
Year to Date
-39.51%
1 Year
+179.38%
Key Figures
5.750Open
5.915High
8.36MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.41%Turnover Ratio
5.680Prev. Close
5.330Low
19.96MTurnover
LossP/E Static
5.88P/B
0.00%Div Yield TTM
-26.48%ROA
9.75052wk High
0.44Volume Ratio
-567.94MNet Profit
346.50MShares
-0.4264EPS TTM
1.53Beta
-39.51%ROE
1.57052wk Low
10.30%Amplitude
92.80%Gross Margin
1.89BMarket Cap
3.30Reward/Risk
4.82%Risk Rate
TradingKey Stock Score of Nuvation Bio Inc
Currency: USD Updated: 2026-07-01Key Insights
Nuvation Bio Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 90 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.30.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Nuvation Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Nuvation Bio Inc Highlights
StrengthsRisks
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Growing
The company is in a growing phase, with the latest annual income totaling USD 62.90M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 62.90M.
Undervalued
The company’s latest PE is -12.71, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 228.36M shares, decreasing 12.58% quarter-over-quarter.
Held by Leon Cooperman
Star Investor Leon Cooperman holds 11.83M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.72.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
12.300
Target Price
+116.55%
Upside Space
Nuvation Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Nuvation Bio Inc Info
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Ticker SymbolNUVB
CompanyNuvation Bio Inc
CEOHung (David T)
Websitehttps://www.nuvationbio.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
FAQs
What is the current price of Nuvation Bio Inc (NUVB)?
The current price of Nuvation Bio Inc (NUVB) is 5.42.
What is the symbol of Nuvation Bio Inc?
The ticker symbol of Nuvation Bio Inc is NUVB.
What is the 52-week high of Nuvation Bio Inc?
The 52-week high of Nuvation Bio Inc is 9.75.
What is the 52-week low of Nuvation Bio Inc?
The 52-week low of Nuvation Bio Inc is 1.57.
What is the market capitalization of Nuvation Bio Inc?
The market capitalization of Nuvation Bio Inc is 1.88B.
Is Nuvation Bio Inc (NUVB) currently rated as Buy, Hold, or Sell?
According to analysts, Nuvation Bio Inc (NUVB) has an overall rating of Buy, with a price target of 12.30.
What is the Earnings Per Share (EPS TTM) of Nuvation Bio Inc (NUVB)?
The Earnings Per Share (EPS TTM) of Nuvation Bio Inc (NUVB) is -0.60.